Charles Semba, MD

Charles has 17 years of clinical drug development experience in retina, ocular surface disease, and glaucoma. He held senior leadership positions at Genentech, Shire, SARcode Bioscience, ForSight VISION5, and Stanford University. At Genentech, he led the clinical development of Lucentis® that resulted in approvals for wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion and directed programs for Activase®, Cathflo Activase®, TNKase®, Lucentis®, Rituximab® [immunology], and Nutropin AQ® . He served as Chief Medical Officer at SARcode and Vice President, Clinical Medicine (Ophthalmology) at Shire and led the development of Xiidra® , the first drug to treat signs and symptoms of dry eye disease; SARcode was acquired by Shire in 2013. Most recently, he was Chief Medical Officer at ForSight VISION5, a clinical-stage company focused on sustained-release drug delivery for glaucoma; ForSight was acquired by Allergan in 2016. Charles received his BA, cum laude, in chemistry at Carleton College; MD from the University of Minnesota; radiology residency at the University of California, San Diego;  and fellowship in endovascular surgery/interventional radiology from the Miami Cardiac and Vascular Institute. He remains an Adjunct Professor of Interventional Radiology at Stanford and has over 100 scientific publications and 25 book chapters, and has received scientific awards in both ophthalmology and radiology.